First-Line Metastatic Urothelial Carcinoma: EV + Pembrolizumab vs Platinum-Based Therapy

Authored by Natalia Gandur, published on 2026-07-24 16:00:29.0

This algorithm (1L Metastatic Urothelial Carcinoma: EV/Pembro vs Platinum) should answer one practical question: In a patient with previously untreated unresectable or metastatic urothelial carcinoma, should first-line therapy be EV + pembrolizumab or platinum-based chemotherapy?The goal is not to recreate a full “Advanced Bladder Cancer” pathway. The goal is to define who should receive EV/pembrolizumab upfront, and when platinum-based chemotherapy followed by maintenance avelumab remains clinically relevant.

Previously Untreated Unresectable Locally Advanced or Metastatic Urothelial Carcinoma (Bladder, Upper Tract, Urethra)
- Confirm First-Line Metastatic Setting
  
  Metastatic or unresectable disease No prior systemic therapy for metastatic disease Establish treatment goals Review prior perioperative therapy (if any) Evaluate disease burden and symptoms
  - Assess Eligibility for EV + Pembrolizumab
    
    Performance Status (ECOG 0–2 preferred) Neuropathy (No baseline ≥ Grade 2) Diabetes/Hyperglycemia risk (Diabetes controlled; manage risk) Skin toxicity risk (No severe active skin disease) Autoimmune disease/IO contraindication (No active AI disease or IO contraindication) Renal function (eGFR ≥ 30 mL/min OK for EV/pembro) Access/logistics (Drug access, infusion feasibility, support system) Patient preference (Discuss goals, benefits, risks, alternatives)
    - Is EV + Pembrolizumab appropriate and feasible?
      
      This decision node is supported indirectly by evidence establishing EV+pembrolizumab benefit (vs platinum chemotherapy) and by prior negative/neutral trials of chemo-IO combinations or IO monotherapy in unselected first-line populations, which contextualize why EV+pembrolizumab is distinct.
      - EV + PEMBROLIZUMAB
        
        Preferred first-line option for eligible patients
        
        Key Considerations
        
        Monitor neuropathy Monitor glucose Monitor skin toxicity Monitor immune-related AEs Assess response every 9 weeks (per local practice)
        
        AFTER FIRST-LINE EV + PEMBROLIZUMAB PROGRESSION
        
        Platinum-based chemotherapy (if eligible and not previously given); FGFR2/3 inhibitor if alteration present; Clinical trial; Other later-line options based on prior therapy, institutional availability, and patient factors
      - Proceed to Platinum Eligibility Assessment
        
        Step 3A: Cisplatin Eligible?
        
        CrCl ≥ 60 mL/min; ECOG 0–1; No Grade ≥ 2 neuropathy; No Grade ≥ 2 hearing loss; No NYHA Class III/IV heart failure
        
        Gemcitabine + CISPLATIN
        
        4–6 cycles
        
        If no progression after 4–6 cycles and no unacceptable toxicity
        
        MAINTENANCE AVELUMAB
        
        Until progression or unacceptable toxicity
        
        AFTER FIRST-LINE PLATINUM-BASED THERAPY PROGRESSION
        
        EV-based therapy (if not previously received); Pembrolizumab (if not previously received and IO-eligible); FGFR2/3 inhibitor if alteration present; Clinical trial and other later-line options
        
        Step 3B: Platinum Eligible (Carboplatin)?
        
        CrCl ≥ 60 mL/min but ≥ 30 mL/min; ECOG 0–2; No prohibitive cytopenias; No severe comorbidities precluding chemo
        
        Step 3C: Platinum Ineligible
        
        CrCl < 30 mL/min; ECOG ≥ 3; Severe comorbidities or frailty; Poor marrow reserve or cytopenias
        
        Step 4: Individualized Approach
        
        Immunotherapy monotherapy (if IO-eligible); EV monotherapy (if available and appropriate); Clinical trial; Best supportive / palliative care
        
        Gemcitabine + CISPLATIN
        
        4–6 cycles
        
        If no progression after 4–6 cycles and no unacceptable toxicity
        
        MAINTENANCE AVELUMAB
        
        Until progression or unacceptable toxicity
        
        AFTER FIRST-LINE PLATINUM-BASED THERAPY PROGRESSION
        
        EV-based therapy (if not previously received); Pembrolizumab (if not previously received and IO-eligible); FGFR2/3 inhibitor if alteration present; Clinical trial and other later-line options
        
        Step 3B: Platinum Eligible (Carboplatin)?
        
        CrCl ≥ 60 mL/min but ≥ 30 mL/min; ECOG 0–2; No prohibitive cytopenias; No severe comorbidities precluding chemo
        
        Step 3C: Platinum Ineligible
        
        CrCl < 30 mL/min; ECOG ≥ 3; Severe comorbidities or frailty; Poor marrow reserve or cytopenias
        
        Step 4: Individualized Approach
        
        Immunotherapy monotherapy (if IO-eligible); EV monotherapy (if available and appropriate); Clinical trial; Best supportive / palliative care
        
        Gemcitabine + CISPLATIN
        
        4–6 cycles
        
        If no progression after 4–6 cycles and no unacceptable toxicity
        
        MAINTENANCE AVELUMAB
        
        Until progression or unacceptable toxicity
        
        AFTER FIRST-LINE PLATINUM-BASED THERAPY PROGRESSION
        
        EV-based therapy (if not previously received); Pembrolizumab (if not previously received and IO-eligible); FGFR2/3 inhibitor if alteration present; Clinical trial and other later-line options
        
        Step 3C: Platinum Ineligible
        
        CrCl < 30 mL/min; ECOG ≥ 3; Severe comorbidities or frailty; Poor marrow reserve or cytopenias
        
        Step 4: Individualized Approach
        
        Immunotherapy monotherapy (if IO-eligible); EV monotherapy (if available and appropriate); Clinical trial; Best supportive / palliative care